TY - JOUR AU - Christopoulos, Petros AU - Kirchner, Martina AU - Endris, Volker AU - Stenzinger, Albrecht AU - Thomas, Michael PY - 2018 TI - EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK + NSCLC JF - Journal of Thoracic Disease; Vol 10, Supplement 17 (June 20, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Anaplastic lymphoma kinase ( ALK ) gene fusions drive approximately 5% of non-small cell lung cancers (NSCLC) (1). Fluorescence in situ hybridization (FISH) and immunohistochemistry are widely used to identify them based on ALK translocation and ALK overexpression, which are common in all cases and equally predict response to tyrosine kinase inhibitors (TKI) (2). On the other hand, the ALK fusion itself varies among patients. UR - https://jtd.amegroups.org/article/view/21407